Biodel Inc (BIOD) 2.28 $BIOD
Biodel to Report Second Quarter Fiscal Year 2014 Financial Results on May 13, 2014
GlobeNewswire - Wed May 07, 3:47PM CDT
Biodel Inc. (Nasdaq:BIOD) will issue its second quarter fiscal year 2014 financial results on May 13, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Osteoporosis - Pipeline Review, H1 2014: 60 Companies and 94 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ff2vx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - Affectis Pharmaceuticals AG - Alethia Biotherapeutics Inc. - Alkem Laboratories Ltd. - Amgen Astellas BioPharma K.K. - Amgen Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Ausio Pharmaceuticals, LLC - Azelon Pharmaceuticals Inc. - B&C Biopharm - Biodel Inc. - Biolo ElexoPharm GmbH - Bone Medical Limited - Bone Therapeutics SA - Calzada Limited - CardioVascular BioTherapeutics, Inc. - Centre de Regulacio Genomica - Chugai Pharmaceutical Co., Ltd. - Shenogen Pharma Group Ltd. - Siena Biotech S.p.A. - TSRL, Inc. - Takeda Pharmaceutical Company Limited - Uni-Bio Science Group Ltd. - Ventria Bioscience - Wroclawskie Centrum Badan EIT Sp. z o.o. - Zealand Pharma A/S - Zosano Pharma, Inc. - Zydus Cadila Healthcare Limited Drug Profiles: - bazedoxifene acetate - denosumab - romosozumab - odanacatib - BA-058 - zoledronic acid - ibandronate sodium - estrone sodium sulfate (levonorgestrel Ethinyl Estradiol) prasterone - teriparatide - COVOP-77 - E-4 - teriparatide - calcitonin - PHN-031 - teriparatide - teriparatide ZP Patch - alendronate sodium - DP-001 - blosozumab - ES-1 - PREOB - AUS-131 - IMD-2560 - MIV-711 - DW-1350 - ZYPH-0907 - OCT-1547 - teriparatide - CDRI-99/373 - VEN-130 For more information visit http://www.researchandmarkets.com/research/4f...teoporosis
Biodel, HEC Pharm Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:30PM CDT
Biodel Inc. (BIOD) signed a research supply and technology development agreement with HEC Pharm for ultra-rapid-acting insulin aspart.
Biodel Announces Collaboration Agreement With HEC Pharm for Development of Ultra-Rapid-Acting Insulin Aspart Formulation
GlobeNewswire - Tue Apr 22, 3:19PM CDT
Biodel Inc. (Nasdaq:BIOD) today announced the signing of a research supply and technology development agreement with the HEC Pharm subsidiary Yichang Chang Jiang Pharmaceutical Co., Ltd for ultra-rapid-acting insulin aspart. Under the agreement, HEC will supply insulin aspart, the active pharmaceutical ingredient (API) in Novolog, which Biodel will use to formulate aspart based ultra-rapid-acting insulin formulations. Biodel has granted HEC an option to enter into negotiations for an exclusive license to develop and market in China any resulting product candidates. Biodel maintains rights to the product candidates in worldwide markets outside of China.
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Biodel enters into commercial manufacturing agreement for Glucagon Rescue Product with Emergent BioSolutions
M2 - Thu Mar 06, 5:05AM CST
Biopharmaceutical company Biodel (NasdaqCM:BIOD) revealed on Wednesday the launch of another agreement for its Glucagon Emergency Management (GEM) development and manufacturing programme with Cangene bioPharma (Emergent BioSolutions).
Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product
GlobeNewswire - Wed Mar 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"
. Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
Traders Get Bullish on Shares of Biodel, Shares Up 7.8% (BIOD)
Comtex SmarTrend(R) - Tue Mar 04, 10:11AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 7.8% to $3.47 on 2.7x average daily volume. Biodel has traded 1.3 million shares thus far today, vs. average volume of 472,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's 1.2%) and outperformed the S&P 500 (7.8% to the S&P's 1.3%) during today's trading.
Biodel to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Biodel Inc. (Nasdaq:BIOD) management will be presenting an overview of the Company's technologies, development programs, and outlook at the 26th Annual ROTH Conference being held at the Ritz-Carlton Laguna Niguel, CA from March 9-12, 2014. Interested parties can access a link to a live webcast of the presentation from the News & Events section of the Biodel website, www.biodel.com. The corporate presentation of the Company will take place on Monday, March 10, 2014 at 4:00 p.m. PT.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Stock to Watch: Biodel Up 5.9% (BIOD)
Comtex SmarTrend(R) - Mon Feb 24, 11:42AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 5.9% to $3.22 on 1.1x average daily volume. Biodel has traded 499,000 shares thus far today, vs. average volume of 447,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's 1.2%) and outperformed the S&P 500 (5.9% to the S&P's 1.2%) during today's trading.
Positive Phase I Data from Biodel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 4:40PM CST
Biodel's BIOD-531 shows positive phase I study results
Hot Stock: Biodel, Shares Gain 6.9% (BIOD)
Comtex SmarTrend(R) - Thu Feb 13, 10:11AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 6.9% to $3.24 on 1.6x average daily volume. Biodel has traded 942,000 shares thus far today, vs. average volume of 603,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 0.0%) and outperformed the S&P 500 (6.9% to the S&P's 0.1%) during today's trading.
CT Lien Solutions Introduces Electronic Signing and Recording Capabilities for Mortgage Documents at MBA National Mortgage Servicing Conference & Expo
Marketwire - Thu Feb 13, 7:30AM CST
WHAT: CT Lien Solutions, a comprehensive provider of lien and document management solutions to mortgage servicers, financial institutions and law firms nationwide, will showcase its expertise in innovative mortgage solutions for mortgage servicers, featuring iLienRED(TM), at the upcoming Mortgage Bankers Association (MBA) National Servicing Conference and Expo February 18-21, 2014 in Orlando, Florida.
Biodel Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 1:49PM CST
Biodel reports a narrower loss in 1Q14.
Biodel Inc announces lower net loss of USD2.4m for Q1 2013
M2 - Fri Feb 07, 7:09AM CST
Biopharmaceutical company Biodel Inc (NasdaqCM:BIOD) on Thursday declared a net loss of USD2.4m, or USD0.12 per share of common stock, for the first fiscal quarter ended 31 December 2013.
Biodel Reports First Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Feb 06, 3:03PM CST
Biodel Inc. (Nasdaq:BIOD) today reported financial results for the first fiscal quarter ended December 31, 2013.
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Biodel to Report First Quarter Fiscal Year 2014 Financial Results on February 6, 2014
GlobeNewswire - Wed Feb 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) will issue its first quarter fiscal year 2014 financial results on February 6, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
Biodel to Report Second Quarter Fiscal Year 2014 Financial Results on May 13, 2014
GlobeNewswire - Wed May 07, 3:47PM CDT
Biodel Inc. (Nasdaq:BIOD) will issue its second quarter fiscal year 2014 financial results on May 13, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Osteoporosis - Pipeline Review, H1 2014: 60 Companies and 94 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ff2vx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - Affectis Pharmaceuticals AG - Alethia Biotherapeutics Inc. - Alkem Laboratories Ltd. - Amgen Astellas BioPharma K.K. - Amgen Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Ausio Pharmaceuticals, LLC - Azelon Pharmaceuticals Inc. - B&C Biopharm - Biodel Inc. - Biolo ElexoPharm GmbH - Bone Medical Limited - Bone Therapeutics SA - Calzada Limited - CardioVascular BioTherapeutics, Inc. - Centre de Regulacio Genomica - Chugai Pharmaceutical Co., Ltd. - Shenogen Pharma Group Ltd. - Siena Biotech S.p.A. - TSRL, Inc. - Takeda Pharmaceutical Company Limited - Uni-Bio Science Group Ltd. - Ventria Bioscience - Wroclawskie Centrum Badan EIT Sp. z o.o. - Zealand Pharma A/S - Zosano Pharma, Inc. - Zydus Cadila Healthcare Limited Drug Profiles: - bazedoxifene acetate - denosumab - romosozumab - odanacatib - BA-058 - zoledronic acid - ibandronate sodium - estrone sodium sulfate (levonorgestrel Ethinyl Estradiol) prasterone - teriparatide - COVOP-77 - E-4 - teriparatide - calcitonin - PHN-031 - teriparatide - teriparatide ZP Patch - alendronate sodium - DP-001 - blosozumab - ES-1 - PREOB - AUS-131 - IMD-2560 - MIV-711 - DW-1350 - ZYPH-0907 - OCT-1547 - teriparatide - CDRI-99/373 - VEN-130 For more information visit http://www.researchandmarkets.com/research/4f...teoporosis
Biodel, HEC Pharm Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:30PM CDT
Biodel Inc. (BIOD) signed a research supply and technology development agreement with HEC Pharm for ultra-rapid-acting insulin aspart.
Biodel Announces Collaboration Agreement With HEC Pharm for Development of Ultra-Rapid-Acting Insulin Aspart Formulation
GlobeNewswire - Tue Apr 22, 3:19PM CDT
Biodel Inc. (Nasdaq:BIOD) today announced the signing of a research supply and technology development agreement with the HEC Pharm subsidiary Yichang Chang Jiang Pharmaceutical Co., Ltd for ultra-rapid-acting insulin aspart. Under the agreement, HEC will supply insulin aspart, the active pharmaceutical ingredient (API) in Novolog, which Biodel will use to formulate aspart based ultra-rapid-acting insulin formulations. Biodel has granted HEC an option to enter into negotiations for an exclusive license to develop and market in China any resulting product candidates. Biodel maintains rights to the product candidates in worldwide markets outside of China.
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Biodel enters into commercial manufacturing agreement for Glucagon Rescue Product with Emergent BioSolutions
M2 - Thu Mar 06, 5:05AM CST
Biopharmaceutical company Biodel (NasdaqCM:BIOD) revealed on Wednesday the launch of another agreement for its Glucagon Emergency Management (GEM) development and manufacturing programme with Cangene bioPharma (Emergent BioSolutions).
Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product
GlobeNewswire - Wed Mar 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"
. Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed. Traders Get Bullish on Shares of Biodel, Shares Up 7.8% (BIOD)
Comtex SmarTrend(R) - Tue Mar 04, 10:11AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 7.8% to $3.47 on 2.7x average daily volume. Biodel has traded 1.3 million shares thus far today, vs. average volume of 472,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's 1.2%) and outperformed the S&P 500 (7.8% to the S&P's 1.3%) during today's trading.
Biodel to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Biodel Inc. (Nasdaq:BIOD) management will be presenting an overview of the Company's technologies, development programs, and outlook at the 26th Annual ROTH Conference being held at the Ritz-Carlton Laguna Niguel, CA from March 9-12, 2014. Interested parties can access a link to a live webcast of the presentation from the News & Events section of the Biodel website, www.biodel.com. The corporate presentation of the Company will take place on Monday, March 10, 2014 at 4:00 p.m. PT.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Stock to Watch: Biodel Up 5.9% (BIOD)
Comtex SmarTrend(R) - Mon Feb 24, 11:42AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 5.9% to $3.22 on 1.1x average daily volume. Biodel has traded 499,000 shares thus far today, vs. average volume of 447,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's 1.2%) and outperformed the S&P 500 (5.9% to the S&P's 1.2%) during today's trading.
Positive Phase I Data from Biodel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 4:40PM CST
Biodel's BIOD-531 shows positive phase I study results
Hot Stock: Biodel, Shares Gain 6.9% (BIOD)
Comtex SmarTrend(R) - Thu Feb 13, 10:11AM CST
Biodel (NASDAQ:BIOD) is one of today's best performing low-priced stocks, up 6.9% to $3.24 on 1.6x average daily volume. Biodel has traded 942,000 shares thus far today, vs. average volume of 603,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 0.0%) and outperformed the S&P 500 (6.9% to the S&P's 0.1%) during today's trading.
CT Lien Solutions Introduces Electronic Signing and Recording Capabilities for Mortgage Documents at MBA National Mortgage Servicing Conference & Expo
Marketwire - Thu Feb 13, 7:30AM CST
WHAT: CT Lien Solutions, a comprehensive provider of lien and document management solutions to mortgage servicers, financial institutions and law firms nationwide, will showcase its expertise in innovative mortgage solutions for mortgage servicers, featuring iLienRED(TM), at the upcoming Mortgage Bankers Association (MBA) National Servicing Conference and Expo February 18-21, 2014 in Orlando, Florida.
Biodel Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 1:49PM CST
Biodel reports a narrower loss in 1Q14.
Biodel Inc announces lower net loss of USD2.4m for Q1 2013
M2 - Fri Feb 07, 7:09AM CST
Biopharmaceutical company Biodel Inc (NasdaqCM:BIOD) on Thursday declared a net loss of USD2.4m, or USD0.12 per share of common stock, for the first fiscal quarter ended 31 December 2013.
Biodel Reports First Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Feb 06, 3:03PM CST
Biodel Inc. (Nasdaq:BIOD) today reported financial results for the first fiscal quarter ended December 31, 2013.
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Biodel to Report First Quarter Fiscal Year 2014 Financial Results on February 6, 2014
GlobeNewswire - Wed Feb 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) will issue its first quarter fiscal year 2014 financial results on February 6, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
